US OptionsDetailed Quotes
VCYT240517C20000
- 3.20
- 0.000.00%
15min DelayClose May 16 09:51 ET
0.00High0.00Low
0.00Open3.20Pre Close0 Volume0 Open Interest20.00Strike Price0.00Turnover0.00%IV7.31%PremiumMay 17, 2024Expiry Date1.62Intrinsic Value100Multiplier-5DDays to Expiry1.58Time Value100Contract SizeAmericanOptions Type--Delta--Gamma6.76Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Veracyte Stock Discussion
Select biotech/pharma names showing strength following ESMO:
$Clovis Oncology(CLVS.US)$ +11.3%, $Cardiff Oncology(CRDF.US)$ +9%, $Immatics(IMTX.US)$ +8.3%, $IDEAYA Biosciences(IDYA.US)$ +8%, $Lyra Therapeutics(LYRA.US)$ +5.7%, $POINT Biopharma(PNT.US)$ +5.7%, $Edgewise Therapeutics(EWTX.US)$ +4.7%, $Concert Pharmaceuticals(CNCE.US)$ +3.6%, $Deciphera Pharmaceuticals(DCPH.US)$ +3.2%, $Veracyte(VCYT.US)$ +2.6%, $SpringWorks Therapeutics(SWTX.US)$ +2.3%,...
• $Theravance Biopharma(TBPH.US)$ +15.9% (TBPH to sell all of its units in Theravance Respiratory to RPRX for over $1.5 bln)
• $Amryt Pharma(AMYT.US)$ +11.9% (FDA grants Orphan Drug Designation to Mycapssa for the treatment of Carcinoid Syndrome)
• $Green Brick Partners(GRBK.US)$ +7.3% (to join S&P SmallCap 600)
• $TransGlobe Energy(TGA.US)$ +6.9% (Transglobe Energy to be acquired by VALLCO Energy (EGY) in stock-for-stock...
• $Microvast(MVST.US)$ +14.6% (In reaction to earnings)
• $Sea(SE.US)$ +11.3% (Q1 adjusted loss expands, revenue jumps)
• $JD.com(JD.US)$ +9.1% (beating top-line and bottom-line estimates for its latest quarter)
• $Coinbase(COIN.US)$ +6.3% (announces it is "slowing hiring so we can reprioritize our hiring needs against our highest-priority business goals")
• $Heliogen(HLGN.US)$ +5%(to restate Full Year 2021 Financials)
• $Take-Two Interactive Software(TTWO.US)$ +4.9% (de...
• $Affirm Holdings(AFRM.US)$ +36.4% (also announces multi-year extension of exclusive partnership with SHOP in the US)
• $Robinhood(HOOD.US)$ +22.9% (Emergent Fidelity discloses 7.6% stake; Sam Bankman-Fried CEO of crypto exchange FTX is majority holder in fund)
• $Endeavor Group(EDR.US)$ +20% (in reaction to earnings)
• $Coinbase(COIN.US)$ +13% (in sympathy with HOOD news)
• $Dynavax Technologies(DVAX.US)$ +11.5% (to join ...
ARK's buys
$Robinhood(HOOD.US)$ $Nu Holdings(NU.US)$ $Veracyte(VCYT.US)$ $Personalis(PSNL.US)$ $PagerDuty(PD.US)$ $Quantum-Si(QSI.US)$
ARK's sells
$Iovance Biotherapeutics(IOVA.US)$ $LivePerson(LPSN.US)$ $3D Systems(DDD.US)$
Veracyte announced that it has begun rolling out its long-awaited nasal swab test for lung cancer at a limited number of clinical sites, as the company continues to accumulate data to support its future full commercial rollout.
The company also published recent findings showing that the Percepta Genomic test can more accurately group patients based on their risk of developing tumors and suspicious lung nodules.
No comment yet